Evaluating the Efficacy and Safety of Apixaban, a New Oral Anticoagulant, using Bayesian Meta-Analysis

Persistent Link:
http://hdl.handle.net/10150/614296
Title:
Evaluating the Efficacy and Safety of Apixaban, a New Oral Anticoagulant, using Bayesian Meta-Analysis
Author:
Ross, Daniel; Malone, Daniel; Villa, Lorenzo A
Affiliation:
College of Pharmacy, The University of Arizona
Issue Date:
2013
Rights:
Copyright © is held by the author.
Collection Information:
This item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.
Publisher:
The University of Arizona.
Abstract:
Specific Aims:  To determine the efficacy of apixaban when compared to LMWH (enoxaparin) when used as thromboprophylaxis for patients undergoing total hip arthroplasty (THA), total knee arthroplasty (TKA), and medically ill patients  To determine the safety of apixaban when compared to LMWH (enoxaparin) when used as thromboprophylaxis for patients undergoing total hip arthroplasty (THA), total knee arthroplasty (TKA), and medically ill patients Methods: A systematic search of the literature for randomized controlled trials of apixaban thromboprophylaxis therapy versus enoxaparin was conducted using three databases: PubMed, EMBASE, and the Cochrane library. Data from five studies with 12,938 total patients were analyzed using Bayesian random effects meta-analysis. To evaluate efficacy, a composite of venous thromboembolism and death during follow-up was measured. To evaluate safety, major and total bleeding events were considered. Main Results: The odds ratio (OR) for the composite outcome of thromboembolism/death was 0.66 (95% CI: 0.33 to 1.29) for apixaban compared to enoxaparin, while there was a similar risk of major bleeding (OR=1.03, 95%CI: 0.36 to 3.73) and total bleeding (OR=0.92, 95%CI: 0.64 to 1.20). Conclusion: These results suggest a lack of clear superiority of apixaban relative to enoxaparin. Apixaban is an oral alternative with similar efficacy and safety to existing anticoagulant therapies.
Description:
Class of 2013 Abstract
Keywords:
apixaban; anticoagulant; Bayesian; hip arthroplasty (THA); total knee arthroplasty (TKA); medically ill
Advisor:
Malone, Daniel; Villa, Lorenzo A

Full metadata record

DC FieldValue Language
dc.contributor.advisorMalone, Danielen
dc.contributor.advisorVilla, Lorenzo Aen
dc.contributor.authorRoss, Danielen
dc.contributor.authorMalone, Danielen
dc.contributor.authorVilla, Lorenzo Aen
dc.date.accessioned2016-06-22T22:44:44Z-
dc.date.available2016-06-22T22:44:44Z-
dc.date.issued2013-
dc.identifier.urihttp://hdl.handle.net/10150/614296-
dc.descriptionClass of 2013 Abstracten
dc.description.abstractSpecific Aims:  To determine the efficacy of apixaban when compared to LMWH (enoxaparin) when used as thromboprophylaxis for patients undergoing total hip arthroplasty (THA), total knee arthroplasty (TKA), and medically ill patients  To determine the safety of apixaban when compared to LMWH (enoxaparin) when used as thromboprophylaxis for patients undergoing total hip arthroplasty (THA), total knee arthroplasty (TKA), and medically ill patients Methods: A systematic search of the literature for randomized controlled trials of apixaban thromboprophylaxis therapy versus enoxaparin was conducted using three databases: PubMed, EMBASE, and the Cochrane library. Data from five studies with 12,938 total patients were analyzed using Bayesian random effects meta-analysis. To evaluate efficacy, a composite of venous thromboembolism and death during follow-up was measured. To evaluate safety, major and total bleeding events were considered. Main Results: The odds ratio (OR) for the composite outcome of thromboembolism/death was 0.66 (95% CI: 0.33 to 1.29) for apixaban compared to enoxaparin, while there was a similar risk of major bleeding (OR=1.03, 95%CI: 0.36 to 3.73) and total bleeding (OR=0.92, 95%CI: 0.64 to 1.20). Conclusion: These results suggest a lack of clear superiority of apixaban relative to enoxaparin. Apixaban is an oral alternative with similar efficacy and safety to existing anticoagulant therapies.en
dc.language.isoen_USen
dc.publisherThe University of Arizona.en
dc.rightsCopyright © is held by the author.en
dc.subjectapixabanen
dc.subjectanticoagulanten
dc.subjectBayesianen
dc.subjecthip arthroplasty (THA)en
dc.subjecttotal knee arthroplasty (TKA)en
dc.subjectmedically illen
dc.titleEvaluating the Efficacy and Safety of Apixaban, a New Oral Anticoagulant, using Bayesian Meta-Analysisen_US
dc.typetexten
dc.typeElectronic Reporten
dc.contributor.departmentCollege of Pharmacy, The University of Arizonaen
dc.description.collectioninformationThis item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.en
All Items in UA Campus Repository are protected by copyright, with all rights reserved, unless otherwise indicated.